Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

Dec 10, 2017 23:00 pm UTC| Business

– Safety and Efficacy Profile Consistent with Previously Reported Data –  – Hemoglobin Increases 1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core Treatment Period – – Two...

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

Dec 10, 2017 22:00 pm UTC| Business

– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty-modified CD19-specific CAR+ T cells –– Point-of-care CD19-specific CAR+ T cells co-expressing mbIL15 with...

Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option

Dec 10, 2017 21:45 pm UTC| Business

BALTIMORE, Md., Dec. 10, 2017 -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the “Algeco Group”) today announced that a finance special purpose vehicle that will be a subsidiary of the Algeco Group...

Exclusive: Today, 9 December 2017, Artprice confirms that the acquisition of Da Vinci's Salvator Mundi involved geopolitical mediation, and that the Vatican Museums did indeed study the offer

Dec 10, 2017 20:59 pm UTC| Business

Artprice confirms the contents of its press release of 8 December and, today (9 December), adds further explanations concerning this historic sale: Artprice Exclusive - Da Vinci's Salvator Mundi at the Louvre Abu...

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

Dec 10, 2017 15:00 pm UTC| Business

CAMBRIDGE, Mass., Dec. 10, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its commitment to...

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

Dec 10, 2017 14:00 pm UTC| Business

39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4high patient population receiving G100+pembrolizumab (potential predictive biomarker)Responses occur in both...

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

Dec 10, 2017 14:00 pm UTC| Business

– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with...